GPAT4, a key triglyceride synthesis enzyme, contributes to MAFLD through abnormal overexpression that causes excessive hepatocellular triglyceride accumulation and disrupts LDs dynamics, while LDHA affects MAFLD progression by altering glycolysis, energy metabolism, and redox state to impact LDs transport and hepatic steatosis. This evidence concerns the gene GPAT4 and fatty liver disease.